Comparative Efficacy and Safety of Enalapril and Sustained-Release Nifedipine in Patients with Mild to Moderate Hypertension

Guéret, Pascal; Artigou, J. Y.; Benichou, M; Berland, Jacques; Fressinaud, P; Grollier, G; Duc, Luu

doi:10.2165/00003495-199000392-00013

Cited by 8 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The studies included participants from a wide range of medical conditions including hypertension, transient ischemic attack, coronary artery disease, proteinuria, heart failure, and organ transplant. The basic characteristics of the studies are in Table 1 15–149 . A total of 44 RCT compared ACEI with placebo, 68 RCT with ARB, and 35 RCT with CCB.…”

Section: Resultsmentioning

confidence: 99%

“…The basic characteristics of the studies are in Table 1 . 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ...…”

Section: Resultsunclassified

See 1 more Smart Citation

Angiotensin‐converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta‐analysis

Liang

Liu

et al. 2023

J of Clinical Hypertension

View full text Add to dashboard Cite

Studies have shown that angiotensin converting enzyme inhibitors (ACEIs) are superior in primary and secondary prevention for cardiac mortality and morbidity to angiotensin receptor blocker (ARBs). One of the common side effects from ACEI is dry cough. The aims of this systematic review, and network meta‐analysis are to rank the risk of cough induced by different ACEIs and between ACEI and placebo, ARB or calcium channel blockers (CCB). We performed a systematic review, and network meta‐analysis of randomized controlled trials to rank the risk of cough induced by each ACEI and between ACEI and placebo, ARB or CCB. A total of 135 RCTs with 45,420 patients treated with eleven ACEIs were included in the analyses. The pooled estimated relative risk (RR) between ACEI and placebo was 2.21 (95% CI: 2.05–2.39). ACEI had more incidences of cough than ARB (RR 3.2; 95% CI: 2.91, 3.51), and pooled estimated of RR between ACEI and CCB was 5.30 (95% CI: 4.32–6.50) Moexipril ranked as number one for inducing cough (SUCRA 80.4%) and spirapril ranked the least (SUCRA 12.3%). The order for the rest of the ACEIs are as follows: ramipril (SUCRA 76.4%), fosinopril (SUCRA 72.5%), lisinopril (SUCRA 64.7%), benazepril (SUCRA 58.6%), quinapril (SUCRA 56.5%), perindopril (SUCRA 54.1%), enalapril (SUCRA 49.7%), trandolapril (SUCRA 44.6%) and, captopril (SUCRA 13.7%). All ACEI has the similar risk of developing a cough. ACEI should be avoided in patients who have risk of developing cough, and an ARB or CCB is an alternative based on the patient's comorbidity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsunclassified

Angiotensin‐converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta‐analysis

Liang

Liu

et al. 2023

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…15,16 The results of this study concur with other results comparing nifedipine SR with other ACE inhibitors. 17,18 …”

Section: Discussionmentioning

confidence: 99%

A Randomized, Double-Blind, Parallel-Group Study to Compare the Anti-Hypertensive Effects of Imidapril and Nifedipine in the Treatment of Mild-to-Moderate Essential Hypertension

Does¹,

Euler

2001

J Int Med Res

View full text Add to dashboard Cite

This 12-week, multicentre, double-blind, placebo-controlled, parallel-group study compared efficacy of the angiotensin-converting enzyme (ACE) inhibitor imidapril 5 - 10 mg/day and the calcium channel blocker nifedipine slow-release (SR) formulation 20 - 40 mg twice daily. In total 320 patients aged 18 - 75 years, with mean sitting diastolic blood pressures of 95 - 115 mmHg, were randomized to treatment with imidapril (n = 157) or nifedipine SR (n = 163). Efficacy evaluations were based on the intent-to-treat principle. On study completion, there was no difference between the groups with respect to the primary efficacy variable of response to treatment (imidapril 63.1%; nifedipine SR 61.3%). After 2 weeks' treatment, clinically relevant decreases in blood pressure were observed in both groups, with a trend towards further reductions until study end. Fewer patients in the imidapril-treated group than the nifedipine group withdrew due to adverse events that occurred on treatment with study medication (3.2% versus 16.0%) or experienced adverse events (40.1% versus 49.7%). In addition, fewer adverse events were causally related to imidapril (24.2%) compared with nifedipine SR (41.7%). These results show that imidapril is effective in the treatment of essential hypertension and is better tolerated than nifedipine SR.

show abstract

Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions

et al. 2023

View full text Add to dashboard Cite

Comparative Efficacy and Safety of Enalapril and Sustained-Release Nifedipine in Patients with Mild to Moderate Hypertension

Cited by 8 publications

References 11 publications

Angiotensin‐converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta‐analysis

Angiotensin‐converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: A systematic review, and network meta‐analysis

A Randomized, Double-Blind, Parallel-Group Study to Compare the Anti-Hypertensive Effects of Imidapril and Nifedipine in the Treatment of Mild-to-Moderate Essential Hypertension

Non-pharmacological and drug treatment of autonomic dysfunction in multiple system atrophy: current status and future directions

Contact Info

Product

Resources

About